December 12, 2017 / 12:51 PM / a month ago

BRIEF-Ablynx Reports Additional Clinically Important Benefits Of Caplacizumab

Dec 12 (Reuters) - ABLYNX NV:

* ABLYNX REPORTS ADDITIONAL CLINICALLY IMPORTANT BENEFITS OF CAPLACIZUMAB FROM ITS PHASE III HERCULES STUDY IN ACQUIRED TTP

* TREATMENT WITH CAPLACIZUMAB RESULTED IN: * 38% RELATIVE REDUCTION IN NUMBER OF DAYS OF PLASMA EXCHANGE (PEX)

* TREATMENT WITH CAPLACIZUMAB RESULTED IN: 41% RELATIVE REDUCTION IN VOLUME OF PLASMA USED

* TREATMENT WITH CAPLACIZUMAB RESULTED IN: 65% RELATIVE REDUCTION IN NUMBER OF DAYS IN INTENSIVE CARE UNIT (ICU)

* OVERALL DURATION OF HOSPITALISATION IN CAPLA GROUP WAS REDUCED BY 31% COMPARED TO PLACEBO GROUP (9.9 DAYS VERSUS 14.4 DAYS, RESPECTIVELY)

* TREATMENT WITH CAPLACIZUMAB RESULTED IN: 31% RELATIVE REDUCTION IN NUMBER OF DAYS IN HOSPITAL Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below